Introducing a new entity: chemotherapy-induced arrhythmia.
about
The tell-tale heart: molecular and cellular responses to childhood anthracycline exposureA novel 3D label-free monitoring system of hES-derived cardiomyocyte clusters: a step forward to in vitro cardiotoxicity testingCancer treatment-related cardiac toxicity: prevention, assessment and management.Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysisRomidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors.Heart repolarization changes after anthracycline therapy in the children with cancerRegulation of SCN3B/scn3b by Interleukin 2 (IL-2): IL-2 modulates SCN3B/scn3b transcript expression and increases sodium current in myocardial cells.Autologous Stem-Cell Transplantation Without Hematopoietic Support for the Treatment of Hematologic Malignancies in Jehovah's WitnessesCardiovascular Toxicity of Molecular Targeted Therapy in Cancer Patients: A Double-Edged SwordValidation of 2 Submaximal Cardiorespiratory Fitness Tests in Patients With Breast Cancer Undergoing ChemotherapyAtrial Function in Patients with Breast Cancer After Treatment with AnthracyclinesDecreased Soluble Guanylate Cyclase Contributes to Cardiac Dysfunction Induced by Chronic Doxorubicin Treatment in Mice.Antineoplastic drug-induced bradyarrhythmias.Cancer chemotherapy and cardiac arrhythmias: a review.Anthracycline-Induced Cardiomyopathy in Adults.Arrhythmias and Other Electrophysiology Issues in Cancer Patients Receiving Chemotherapy or Radiation.An integrative view of cisplatin-induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures.Analysis of the costs and quality of cardiovascular care in oncological monitoring.Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs.Cisplatin-induced sudden cardiac death with hemodynamic collapse: a severe adverse drug reaction: Case report.Doxorubicin-induced changes of ventricular repolarization heterogeneity: results of a chronic rat study.European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm SocieAnthracycline-induced acute myocarditis and ventricular fibrillation arrest.Rates and risk of arrhythmias in cancer survivors with chemotherapy-induced cardiomyopathy compared with patients with other cardiomyopathies.A Case of Myocarditis and Near-Lethal Arrhythmia Associated With Interleukin-2 Therapy.Cisplatin and cisplatin analogues perfusion through isolated rat heart: the effects of acute application on oxidative stress biomarkers.Cardio-Oncology - A new subspecialty with collaboration at its heart.Protective effects of curcumin and beta-carotene on cisplatin-induced cardiotoxicity: An experimental rat model.Effects of anthracycline, cyclophosphamide and taxane chemotherapy on QTc measurements in patients with breast cancer.European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm SocietAnticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms
P2860
Q26823592-82617FD7-70F7-4FD8-919B-825883F3EDACQ27311346-9B55C022-EEB8-45AD-BAD6-E136FD6A292DQ30276456-FCE3C9AC-5F59-4223-B206-7EE27391BC4EQ30897591-FB8EC280-BCA9-4A72-8C4F-8F28C6C9507EQ33390876-3E7DF6A1-A4AD-4AB3-AFA1-C56ED89C256BQ34234872-DEE9A5AB-B18E-48DE-A8BC-572661C92D82Q35884552-0952DEC3-E3DF-423F-876D-41994112C770Q36025989-5338C15B-07BB-46CA-A5CB-E9B28AE59D47Q36721511-AF66AAEF-1825-4ED4-B83A-D291AC703951Q37309577-715B2C23-AC6B-4605-92E8-F225A2594A22Q37472884-5B15DC4D-BFFC-468A-99C1-ED167E426218Q37613120-A0EEA8BE-45E9-4053-9931-E4669D0C8952Q38025714-EC87EE43-3D30-400F-AFEE-ECA53174C959Q38313870-59B7C8C5-B2B2-42AF-86DC-C41137232107Q38542462-71B628AF-2815-4B3B-8979-F1326D7AD662Q38815946-97759A83-AEFA-4FF4-86A1-9CD72881338CQ38975452-1FC76EA3-64D4-4B7A-93B5-4CE1008931E6Q39089348-2C8F37DF-78F5-479E-BE72-3596C74AF91BQ40885464-3154510B-D61E-4D41-92D2-83EDAC40C66CQ47124163-CABEF260-57EA-4DA5-BD28-F4B53581C9C5Q47726932-67E8ADFB-98C6-4A36-AB4B-5F5506D04BB8Q47796802-7E141468-81DF-4B7F-A9EA-F7A95D91C1E6Q48197118-6D9EED30-BE03-40D4-9151-ACF045D4186EQ48222615-87CB5A86-1AF4-4622-89F5-721BB39FF734Q49332278-951A86CB-BB99-42F9-845E-48429B0D41DEQ52553038-BB9E9626-E6CE-400A-B5C8-2A5379C8BAC9Q53104651-33435225-16DD-4836-AE49-8EA135982749Q55018308-8B2C9B5C-9F3A-4E1A-979E-2A7C1586EFFDQ55262271-AE6224B4-1F32-488E-AC31-30859400EBD6Q57072097-28C4ED54-2E47-4245-8990-C29A203E624BQ58554222-8A212D61-9DB0-4AA6-B75A-240DA9B61766
P2860
Introducing a new entity: chemotherapy-induced arrhythmia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Introducing a new entity: chemotherapy-induced arrhythmia.
@en
Introducing a new entity: chemotherapy-induced arrhythmia.
@nl
type
label
Introducing a new entity: chemotherapy-induced arrhythmia.
@en
Introducing a new entity: chemotherapy-induced arrhythmia.
@nl
prefLabel
Introducing a new entity: chemotherapy-induced arrhythmia.
@en
Introducing a new entity: chemotherapy-induced arrhythmia.
@nl
P2093
P2860
P356
P1433
P1476
Introducing a new entity: chemotherapy-induced arrhythmia
@en
P2093
Anne B Curtis
Mohsen Aljayeh
Saleemuddin Saiyad
P2860
P304
P356
10.1093/EUROPACE/EUP300
P50
P577
2009-10-03T00:00:00Z